As of Sep 30
| +0.24 / +1.16%|
The 6 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 44.00, with a high estimate of 60.00 and a low estimate of 20.00. The median estimate represents a +110.73% increase from the last price of 20.88.
The current consensus among 7 polled investment analysts is to Buy stock in Acorda Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.